Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.

导出 OA

翻译打印收藏纠错

作者： Roberto,Rossotti ^[1] ; Giovanna,Travi ^[2] ; Nicola,Ughi ^[3] ; Matteo,Corradin ^[4] ; Chiara,Baiguera ^[2] ; Roberto,Fumagalli ^[5] ; Maurizio,Bottiroli ^[6] ; Michele,Mondino ^[6] ; Marco,Merli ^[2] ; Andrea,Bellone ^[7] ; Andriano,Basile ^[7] ; Ruggero,Ruggeri ^[8] ; Fabrizio,Colombo ^[8] ; Mauro,Moreno ^[4] ; Stefano,Pastori ^[9] ; Carlo Federico,Perno ^[10] ; Paolo,Tarsia ^[11] ; Oscar Massimiliano,Epis ^[3] ; Massimo,Puoti ^[2] ; Niguarda COVID-19 Working Group

作者单位： Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy. Electronic address: roberto.rossotti@ospedaleniguarda.it. ^[1] Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy. ^[2] Rheumatology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. ^[3] Healthcare Management Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. ^[4] Department of Anaesthesia and Critical Care, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. ^[5] Department of Anaesthesia and Critical Care, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. ^[6] Emergency Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. ^[7] Internal Medicine Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. ^[8] Chemical-Clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. ^[9] Chemical-Clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Oncohematology, University of Milan, Milan, Italy. ^[10] Pneumology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. ^[11]

关键词 COVID-19 IL-6 Orotracheal tube SARS-CoV2 Tocilizumab